William Barton / Shutterstock.com

29 January 2025NewsAmericasMuireann Bolger

GSK seeks damages hike in ‘skinny label’ case

Complex legal battle concerns ‘skinny label’ strategy used by generic drug makers, prompting a $235 million award | Pharma giant looks for enhanced damages due to ‘wilful infringement’, while opponent wants another trial.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

16 May 2023 The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.

Effects of GSK v Teva ripple after SCOTUS denies cert

23 May 2023 Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.

More on this story

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

16 May 2023 The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.

Effects of GSK v Teva ripple after SCOTUS denies cert

23 May 2023 Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.

More on this story

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

16 May 2023 The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.

Effects of GSK v Teva ripple after SCOTUS denies cert

23 May 2023 Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.

More features

UPC orders Sanofi to fix ‘deficiencies’ in prostate cancer drug case

Dutch court axes Biogen’s MS patent, clearing way for generics

Munck Wilson Mandala brings in first-chair patent litigator from McGuireWoods

Goodwin hires ‘impressive’ partner for NY office

Fed Circ grants Teva temporary pause in Orange Book feud

ADCs, TCR, and multimodal AI: Transformative trends in 2025

Acting USPTO director sworn in moments after Trump takes office

UKIPO’s new patent search tool marks ‘generational leap’